NCT05831644View on ClinicalTrials.gov

A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

June 16, 2023

Study Completion Date

June 20, 2023

Conditions

Type2diabetesEndothelial Dysfunction

Interventions

DRUG

C21

C21 is an angiotensin II type 2 receptor agonist (ATRAG)

Trial Locations (1)

20502

Skånes universitetssjukhus, Malmo

All Listed Sponsors

lead

Vicore Pharma AB

INDUSTRY